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The fast-acting β-1 blocker esmolol has been the
center of attention since the landmark article by
Morrelli and colleagues suggesting that, in patients
with sepsis, reducing heart rate by administering
esmolol can result in a survival benefit. However, the
use of esmolol for the treatment of sepsis and the
underlying mechanism responsible for this benefit
remain controversial. This commentary discusses the
study by Jacquet-Lagrèze and colleagues, who in a
pig model of sepsis tested the hypothesis that
administration of esmolol to reduce heart rate may
correct sepsis-induced sublingual and gut
microcirculatory alterations which are known to be
associated with adverse outcome.by the improved survival study in patients with sepsis bySepsis is one of the most complex syndromes to manage
in clinical medicine today. This is because its patho-
physiology is incompletely understood. It is character-
ized by an inflammatory storm leading to cardiovascular
compromise resulting in cellular dysfunction and ultim-
ately to organ failure. Its pathogenesis changes rapidly in
time, and so monitoring its progress is challenging be-
cause conventional monitoring devices are able to meas-
ure only systemic hemodynamic variables whereas the
pathogenesis of sepsis resides at the microcirculation
and the parenchymal cells. Given this background it is
understandable that the search for effective therapeutic
strategies remains wanting since it is difficult to assess
whether the physiological concept on which a therapy is
based—which ultimately must be related to improved
parenchymal perfusion, oxygenation, or function or a
combination of these—is indeed being affected. That isCorrespondence: c.ince@erasmusmc.nl
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creativecommons.org/publicdomain/zero/1.0/why experimental investigations in animal models, which
provide a deeper insight into underlying mechanisms,
are helpful. If novel monitoring techniques which can be
translationally applied to patients are also used, such
studies are especially relevant for the introduction of
new treatment modalities.
In such a study, Jacquet-Lagrèze and colleagues inves-
tigated the possible beneficial effect of the fast-acting β-
1 blocker, esmolol, in improving sublingual and gut
microcirculation in a porcine model of sepsis [1]. The
study is opportune because, even though there is a the-
oretical benefit for administering a β-blocker to reduce
heart rate (HR) and control the adverse effects of an
adrenergic storm associated with sepsis, there is uncer-
tainty about which precise mechanism affected by β-
blockers causes a potential therapeutic benefit. Fuelled
Morelli and colleagues [2], various mechanisms of ac-
tion, including hemodynamic, inflammatory, metabolic,
and coagulation effects, have been proposed [3]. The
most obvious advantage for the use of a β-blocker, how-
ever, remains the expected preservation or improvement
of stroke volume because of a longer diastolic filling
time associated with the reduction in HR. However, even
though almost all studies show an HR reduction follow-
ing esmolol administration, conflicting effects on cardiac
hemodynamics have been reported. Morelli and col-
leagues, in their original study, reported that the ex-
pected increase in stroke volume in patients with
esmolol-treated sepsis was associated with a reduction in
HR [2]. In a subsequent study, however, in which they
reported an improved sublingual microcirculation in re-
sponse to esmolol, they found no such increase in stroke
volume [4]. In a porcine model of hypodynamic sepsis,
Aboab and colleagues found that esmolol causes a stroke
volume increase associated with a reduced HR [5]. In
the present study, however, also in a porcine model,
Jacquet-Lagrèze and colleagues found that the reduction
in HR was not accompanied by a rise in stroke volume.buted under the terms of the Creative Commons Attribution 4.0 International
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esmolol actually does to septic cardiac hemodynamics.
Nevertheless, it cannot be denied that tachycardia in
critically ill patients has a bad prognosis and treating it
(for example, by a β-blocker) remains an attractive op-
tion. Indeed, in a multi-center international observa-
tional trial in 530 mixed intensive care patients, we
showed that tachycardia was the single most sensitive
parameter for predicting adverse outcome [6]. If in
addition to tachycardia there were signs of microcircula-
tory alterations as measured by the same handheld
microscopes used in the present study, prognosis for ad-
verse outcome increased by 80 %.
In their study, Jacquet-Lagrèze and colleagues set out
to achieve a hyperdynamic sepsis model by infusing live
bacteria to target an increase in pulmonary arterial pres-
sures [1]. Though effective in increasing pulmonary ar-
terial pressure, this strategy did not significantly alter
any systemic or metabolic parameters, and their model
could better be described as a normotensive model of
sepsis. Of specific interest and relevance of their septic
model, however, was the finding that, despite normal
systemic and cardiac hemodynamics, severe microcircu-
latory alterations were observed sublingually and in the
gut, a condition similarly reported in several clinical
studies in sepsis and shown to be associated with in-
creased morbidity and mortality [7, 8]. The response to
esmolol in their study, however, had marginal effect on
the sublingual and gut microcirculation, which remained
depressed. This finding in itself is important because it
suggests that, even though systemic hemodynamic vari-
ables may be within the boundaries of normality, sepsis-
induced microcirculatory alterations are not corrected
by esmolol despite a reduction in HR. Nevertheless, the
authors somewhat surprisingly conclude that “esmolol
provided a maintenance of microcirculation, despite its
negative aspects on macrocirculation” [1]. Instead, it
may be more correct to conclude that esmolol, despite
providing a reduction in HR, showed no benefit in their
normotensive model of sepsis with microcirculatory al-
terations. There remains the explanation, though statisti-
cally not significant, regarding the trend to improved gut
microcirculation. This could have been caused by a re-
distribution of blood flow in favor of the gut. Measure-
ment of arterial mesenteric blood flow would have been
helpful in this context. This trend to improved gut
microcirculation in the group statistics could also be ex-
plained by the increased use of milrinone in the esmolol
group. This is significant because other inodilators such
as levosimendan have been described in clinical and ani-
mal studies at improving microcirculatory perfusion and
tissue oxygenation [9, 10]. For a true evaluation of their
results, it would have been better to exclude the experi-
ment in which milrinone was administered. In addition,though not investigated, the slight increase in gut micro-
circulation could be attributed to the anti-inflammatory
effect of esmolol in terms of reported reductions of
tumor necrosis factor-alpha and nuclear factor-kappa-
beta in animal models of sepsis [11, 12]. Despite these
considerations, the lack of improvement of sublingual
microcirculation in their study remains worrying and
does not bode well for these septic pigs since a sustained
depressed sublingual microcirculation is a well-known
indicator of adverse outcome. But this does leave un-
answered the question of whether β-1 blockers are indeed
of benefit in the treatment of hemodynamic alterations as-




The author has received honoraria and independent research grants from
Fresenius-Kabi (Bad Homburg, Germany), Baxter Health Care (Deerfield, IL,
USA), and AM-Pharma (Bunnik, The Netherlands). He has developed
sidestream dark field imaging and is listed as inventor on related patents
commercialized by MicroVision Medical (MVM) under a license from the
Academic Medical Center. He has been a consultant for MVM in the past but
has not been involved with this company for more than 5 years, but he still
holds shares. Braedius Medical (Huizen, The Netherlands), a company owned
by a relative of his, has developed and designed a handheld microscope
called CytoCam-IDF imaging. He has no financial relation with Braedius
Medical of any sort; that is, he has never owned shares or received consultancy
or speaker fees from Braedius Medical.
References
1. Jacquet-Lagrèze M, Allaouchiche B, Restagno D, Paquet C, Ayoub JY,
Etienne J, et al. Gut and sublingual microvascular effect of esmolol during
septic shock in a porcine model. Crit Care. 2015;4:19–241.
2. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al.
Effect of heart rate control with esmolol on hemodynamic and clinical
outcomes in patients with septic shock: a randomized clinical trial. JAMA.
2013;310:1683–91.
3. de Montmollin E, Aboab J, Arnaud Mansart A, Annane D. Bench-to-bedside
review: beta-adrenergic modulation in sepsis. Crit Care. 2009;13:230.
4. Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, et al.
Microvascular effects of heart rate control with esmolol in patients with
septic shock: a pilot study. Crit Care Med. 2013;41:2162–8.
5. Aboab J, Sebille V, Jourdain M, Mangalaboyi J, Gharbi M, Mansart A, et al.
Effects of esmolol on systemic and pulmonary hemodynamics and on
oxygenation in pigs with hypodynamic endotoxin shock. Inten Care Med.
2011;37:1344–51.
6. Vellinga NA, Boerma EC, Koopmans M, Donati A, Dubin A, Shapiro NI, et al.
International study on microcirculatory shock occurrence in acutely ill
patients. Crit Care Med. 2015;43:48–56.
7. De Backer D, Donadello K, Sakr Y, Ospina-Tascon G, Salgado D, Scolletta S,
et al. Microcirculatory alterations in patients with severe sepsis: impact of
time of assessment and relationship with outcome. Crit Care Med.
2013;41:791–9.
8. Edul VS, Enrico C, Laviolle B, Vazquez AR, Ince C, Dubin A. Quantitative
assessment of the microcirculation in healthy volunteers and in patients
with septic shock. Crit Care Med. 2012;40:1443–8.
9. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, et al.
Levosimendan but not norepinephrine improves microvascular oxygenation
during experimental septic shock. Crit Care Med. 2008;36:1886–91.
10. Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, et al.
Levosimendan for resuscitating the microcirculation in patients with septic
shock: a randomized controlled study. Crit Care. 2010;14:R232.
Ince Critical Care  (2015) 19:339 Page 3 of 311. Kimmoun A, Louis H, Kattani NA, Delemazure J, Dessales N, Wei C, et al.
β1-Adrenergic inhibition improves cardiac and vascular function in
experimental septic shock. Crit Care Med. 2015;43:e332–40.
12. Mori K, Morisaki H, Yajima S, Suzuki T, Ishikawa A, Nakamura N, et al. Beta-1
blocker improves survival of septic rats through preservation of gut barrier
function. Intens Care Med. 2011;37:1849–56.
